Conference Call with Advanced Enzyme Technologies Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
Biotechnology company Advanced Enzyme Technologies declares Q3FY22 result: Revenue from operations on consolidated basis decreased to Rs 1,336 million in the Q3 FY22 from Rs 1,377 million in the Q3 FY21, showcasing a slight decline of 3%. Profit: Consolidated EBITDA during Q3 FY22 stands at Rs 491 million as compared to Rs 664 million during Q3 FY21, decrease of 26%. Profit before tax stands at Rs 412 million during Q3 FY22 as against Rs 609 million in Q3 FY21, decline of 32%. Profit after tax de-grew by 35% and stands at Rs 286 million during Q3 FY22 as compared to Rs 443 million during the Q3 FY21. Margin: EBITDA margin stands at 37%, PBT margin stands at 31% and PAT margin stands at 21% during the quarter. Financial costs stood at Rs 3 million, remain unchanged during the during Q3 FY22 on YoY basis Depreciation and Amortization charge for the Q3 FY22 is Rs 88 million as compared to Rs 65 million in the same quarter the previous year. Earnings Per Share during Q3 FY22 stands at Rs 2.46 as compared to Rs 3.86 in Q3 FY21. Result PDF
Highlights: Revenue from Operations: Revenue from operations on consolidated basis increased to Rs 1,271 million in the Q2 FY22 from Rs 1,204 million in the Q2 FY21, showcasing a growth of 6%. Profit: Consolidated EBITDA during Q2 FY22 stands at Rs 493 million as compared to Rs 591 million during Q2 FY21, decrease of 17%. Profit before tax stands at Rs 413 million during Q2 FY22 as against Rs 520 million in Q1 FY21. Profit after tax stands at Rs 303 million during Q2 FY22 as compared to Rs 386 million during the Q2 FY21. Margin: EBITDA margin stands at 39%, PBT margin stands at 32% and PAT margin stands at 24% during the quarter. Financial Costs: Financial costs declined by 22% to Rs 3 million during Q2 FY22 on y-o-y basis and by 34% on q-o-q basis Depreciation and Amortization: Depreciation and Amortization charge for the Q2 FY22 is Rs 86 million as compared to Rs 68 million in the same quarter previous year Earnings Per Share: Earnings Per Share during Q2 FY22 stands at Rs 2.66 as compared to Rs 3.33 in Q2 FY21 Result PDF
Advanced Enzyme Technologies Limited announces Financial Results for First Quarter ended June 2021 Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes, today announced their unaudited financial results for first quarter ended June 2021. CONSOLIDATED FINANCIAL REVIEW (Y-o-Y basis): Revenue from Operations: Revenue from operations on consolidated basis increased to Rs 1,370 million in the Q1 FY22 from Rs 1,105 million in the Q1 FY21, showcasing a growth of 24%. Profit : Consolidated EBITDA during Q1 FY22 stands at Rs 628 million as compared to Rs 517 million during Q1 FY21, increase of 21%. Profit before tax stands at Rs 550 million during Q1 FY22 as against Rs 498 million in the previous year, a Y-o-Y growth of 10%. Profit after tax stands at Rs 399 million during Q1 FY22 as compared to Rs 348 million during the Q1 FY21, a growth of 15%. Margin EBITDA margin during Q1 FY22 stands at 46% as compared to 47% in Q1 FY21. PBT margin stands at 40% during Q1 FY22 as against 45% in the Q1 FY21. PAT margin stands at 29% during Q1 FY22 as against 31% in Q1 FY21. Financial Costs: Financial costs remained flat at Rs 5 million during the quarter. Depreciation and Amortization: Depreciation and Amortization charge for the Q1 FY22 is Rs 83 million as compared to Rs 67 million in the same quarter previous year. The increase is mainly on the account of SciTech Specialties Pvt. Ltd. (SSPL) consolidation in Q1 FY22 (SSPL was acquired on Jan 11, 2021). Earnings Per Share: Earnings Per Share during Q1 FY22 stands at Rs 3.40 as compared to Rs 3.13 in Q1 FY21. Result PDF